J.L. Schultze
Department of Adult Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston
USA
Name/email consistency: high
- Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens. Schultze, J.L., Maecker, B., von Bergwelt-Baildon, M.S., Anderson, K.S., Vonderheide, R.H. Vox Sang. (2001)
- A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2. Schultze, J.L., Anderson, K.C., Gilleece, M.H., Gribben, J.G., Nadler, L.M. Br. J. Haematol. (2001)
- From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Schultze, J.L., Vonderheide, R.H. Trends Immunol. (2001)
- Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?. Schultze, J.L. Leuk. Lymphoma (1999)
- T cell mediated immunotherapy for B cell lymphoma. Schultze, J.L., Nadler, L.M. J. Mol. Med. (1999)
- An array of immunotherapeutic strategies for B-cell lymphomas. Schultze, J.L. Expert. Opin. Investig. Drugs (1999)
- CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. Schultze, J.L., Michalak, S., Seamon, M.J., Dranoff, G., Jung, K., Daley, J., Delgado, J.C., Gribben, J.G., Nadler, L.M. J. Clin. Invest. (1997)
- Vaccination as immunotherapy for B cell lymphoma. Schultze, J.L. Hematol. Oncol (1997)